Isomorphic Labs
Ceren Ozek, PhD, is a seasoned researcher currently serving as a Senior Research Investigator at Isomorphic Labs since December 2023. Prior to this role, Ceren held positions at BenevolentAI as a Senior Drug Discovery Scientist and Biology Project Leader, where leadership in the biology strategy for Parkinson's Disease discovery programs and involvement in target identification were key contributions. Experience also includes serving as a Senior Research Scientist at MiNA Therapeutics, focusing on collaborations related to metabolic diseases, as well as extensive postdoctoral research at Harvard University under Dr. Lee Rubin. Ceren completed a PhD in Neuroscience at the University of Pennsylvania, exploring BDNF/TrkB signaling related to metabolic diseases and previous engagement in summer research internships at prestigious institutions like Harvard and Yale. Ongoing education includes participation in Harvard Medical School's HMX Pro Fundamentals Pharmacology Essentials program.
Isomorphic Labs
7 followers
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.